Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19182366 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19173537 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | April 2025 | August 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 19032963 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3,-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | January 2025 | August 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18988090 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Abandon | 6 | 1 | 0 | No | No |
| 18988163 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Abandon | 6 | 1 | 0 | No | No |
| 18913645 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | October 2024 | April 2025 | Allow | 6 | 1 | 1 | No | No |
| 18805702 | Diagnosis and Treatment of Vitiligo | August 2024 | May 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18792836 | METHODS OF TREATING BRAIN DISORDERS | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18776040 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | July 2024 | January 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18747376 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | June 2024 | July 2025 | Allow | 13 | 1 | 1 | No | No |
| 18744484 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | June 2024 | May 2025 | Allow | 11 | 1 | 0 | No | No |
| 18743233 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | June 2024 | May 2025 | Allow | 11 | 1 | 0 | No | No |
| 18743475 | SARS-COV2 MAIN PROTEASE INHIBITORS | June 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18735898 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | June 2024 | February 2026 | Allow | 20 | 1 | 1 | No | No |
| 18734105 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | June 2024 | December 2024 | Allow | 6 | 1 | 1 | No | No |
| 18675584 | PIKfyve Inhibitors | May 2024 | June 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18632909 | ULTRA BRIGHT DIMERIC OR POLYMERIC DYES | April 2024 | November 2025 | Allow | 19 | 1 | 1 | No | No |
| 18632135 | USE OF IMMUNE MODULATORS TO IMPROVE NERVE REGENERATION | April 2024 | August 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18596586 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18584272 | VANADIUM ALKYLIDENE COMPLEX, SYNTHESIS AND USE THEREOF | February 2024 | September 2024 | Allow | 6 | 1 | 1 | No | No |
| 18582218 | IRAK DEGRADERS AND USES THEREOF | February 2024 | October 2024 | Allow | 8 | 0 | 0 | No | No |
| 18441939 | USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION | February 2024 | March 2026 | Allow | 25 | 2 | 0 | Yes | No |
| 18430056 | C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOF | February 2024 | February 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18410786 | Methods of Modifying Neuronal Function by Changing Intracellular Magnesium Levels | January 2024 | August 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18576499 | POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE | January 2024 | February 2026 | Allow | 26 | 0 | 0 | No | No |
| 18393778 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | December 2023 | October 2024 | Allow | 10 | 1 | 0 | No | No |
| 18530758 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | December 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18565612 | PROCESSES FOR THE PREPARATION OF INHIBITORY COMPOUNDS | November 2023 | February 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18505719 | USP30 INHIBITORS AND USES THEREOF | November 2023 | September 2025 | Allow | 23 | 2 | 1 | No | No |
| 18496049 | NEW COMPOUNDS AND METHODS OF THEIR MANUFACTURING | October 2023 | August 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18492709 | FORMULATIONS FOR HAIR GROWTH | October 2023 | September 2025 | Allow | 23 | 1 | 1 | No | No |
| 18491524 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18379576 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | October 2023 | April 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18485093 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | October 2023 | October 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18480442 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18283867 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | September 2023 | January 2026 | Allow | 28 | 0 | 0 | No | No |
| 18372210 | Lithium Conducting Carbon Phosphonitrides from Substituted Cyanophosphine | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18371722 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | September 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18370186 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | September 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18282677 | USE OF PANTETHINE FOR THE TREATMENT OF SARS COV-2 INFECTIONS | September 2023 | January 2026 | Allow | 28 | 0 | 0 | No | No |
| 18282718 | FLUORINATED PYRIMIDINE COMPOUND AND METHOD FOR PRODUCING SAME | September 2023 | December 2025 | Allow | 27 | 0 | 0 | No | No |
| 18281943 | PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID | September 2023 | January 2026 | Allow | 28 | 0 | 0 | No | No |
| 18244659 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18241583 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | September 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18456145 | 1,1-Dimethyl-2-[(E)-2-phenylethenyl]-1H-benzo[e]indole derivatives and uses thereof | August 2023 | November 2025 | Allow | 27 | 1 | 0 | No | No |
| 18236532 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | August 2023 | July 2024 | Allow | 11 | 1 | 0 | No | No |
| 18275612 | USE OF SILICON COMPOUNDS IN CYCLIZATION REACTIONS | August 2023 | March 2026 | Allow | 31 | 1 | 0 | No | No |
| 18354163 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18212375 | HYDROXYNORKETAMINE FOR THE USE IN THE TREATMENT OF DEPRESSION | June 2023 | October 2024 | Allow | 16 | 1 | 1 | No | No |
| 18206076 | NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION | June 2023 | March 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18329345 | DPEP-1 Binding Compositions and Methods of Use | June 2023 | October 2025 | Allow | 29 | 2 | 1 | No | No |
| 18328267 | Process For Preparing Aminopyrimidine Derivatives | June 2023 | August 2024 | Allow | 15 | 2 | 0 | No | No |
| 18328350 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | June 2023 | September 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18200410 | Methods of Modifying Neuronal Function by Changing Intracellular Magnesium Levels | May 2023 | December 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18253306 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18196128 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | May 2023 | July 2024 | Allow | 14 | 1 | 1 | No | No |
| 18309992 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | May 2023 | November 2024 | Allow | 18 | 1 | 1 | No | No |
| 18033728 | METHOD OF PREPARING SYMMETRICAL PHOSPHATE-BASED COMPOUND | April 2023 | August 2025 | Allow | 28 | 0 | 0 | No | No |
| 18305911 | IRAK DEGRADERS AND USES THEREOF | April 2023 | November 2023 | Allow | 6 | 0 | 0 | No | No |
| 18031836 | VITAMIN D3 PHOSPHATE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHODS FOR PREPARING THE COMPOUND | April 2023 | July 2025 | Allow | 27 | 1 | 1 | No | No |
| 18030728 | PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS | April 2023 | November 2025 | Allow | 31 | 1 | 1 | No | No |
| 18043178 | SURFACTANTS | February 2023 | May 2025 | Allow | 26 | 1 | 0 | No | No |
| 18113549 | CONJUGATES INCLUDING A DETECTABLE MOIETY | February 2023 | March 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 18113047 | Non-distillative Process for Manufacturing High Purity Amphetamines | February 2023 | December 2024 | Allow | 22 | 1 | 1 | No | No |
| 18018393 | Indole Alkaloid With Fungicidal Effect | January 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18015661 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | January 2023 | October 2025 | Allow | 33 | 1 | 0 | No | No |
| 18004952 | 1-ALKYL-5-ARYLIDENE-2-SELENOXOIMIDAZOLIDINE-4-ON AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION COMPRISING SAME FOR PREVENTING, ALLEVIATING OR TREATING NEURODEGENERATIVE DISEASES | January 2023 | October 2025 | Allow | 33 | 1 | 0 | No | No |
| 18093569 | CRYSTALLINE FORMS OF ERAVACYCLINE | January 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18004313 | MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | January 2023 | June 2025 | Allow | 29 | 0 | 0 | No | No |
| 18013681 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | December 2022 | August 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18013431 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | December 2022 | December 2025 | Allow | 36 | 2 | 1 | No | No |
| 17904464 | NOVEL PHOTOSENSITIZER | December 2022 | June 2025 | Allow | 34 | 0 | 0 | No | No |
| 18062644 | AMINO-PYRIMIDINE AMIDES | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18075386 | ANALOGS OF CYCLOBENZAPRINE AND AMITRYPTILENE | December 2022 | July 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18060673 | TUNING SULFONATION AND CONTROLLING OLEO-FURAN SURFACTANT COMPOSITIONS | December 2022 | October 2025 | Allow | 35 | 0 | 0 | No | No |
| 18072154 | ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME | November 2022 | November 2024 | Allow | 24 | 2 | 0 | No | Yes |
| 18072246 | PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | November 2022 | January 2026 | Allow | 38 | 2 | 0 | No | Yes |
| 17999337 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR TREATING OR PREVENTING NEURAL DAMAGE, NEURAL DISEASE, OR DEVELOPMENTAL DISORDER THROUGH PROMOTING PROLIFERATION, DIFFERENTIATION, AND/OR REGENERATION OF NEURAL CELLS | November 2022 | July 2025 | Allow | 32 | 0 | 1 | No | No |
| 17999315 | TETRAHYDROCANNABINOLIC ACID COCRYSTALS | November 2022 | May 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17984011 | COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17997597 | METHODS OF PREPARING SYNTHETIC CANNABICHROMENE AND CANNABICITRAN AND DERIVATIVES THEREOF | October 2022 | December 2024 | Allow | 25 | 0 | 0 | No | No |
| 17997483 | SPIROUREA DERIVATIVES | October 2022 | December 2024 | Allow | 26 | 0 | 0 | No | No |
| 17996633 | TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3 | October 2022 | July 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17961020 | Phosphonium Compound, Reagent Kit for Derivatization, Mass Spectrometric Method, and Method for Producing Phosphonium Compound | October 2022 | January 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 17915675 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR AMELIORATING, OR PREVENTING VIRAL INFECTIONS | September 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 17907244 | METHOD FOR SYNTHESIZING OXETANE COMPOUND BY MICROREACTOR | September 2022 | October 2025 | Allow | 37 | 0 | 0 | No | No |
| 17944821 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | September 2022 | December 2025 | Allow | 39 | 6 | 1 | Yes | No |
| 17906132 | Compounds and Method of Treating COVID-19 | September 2022 | April 2025 | Allow | 31 | 0 | 0 | No | No |
| 17910037 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | September 2022 | January 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 17909131 | Arylcyclohexylamine derivatives and process for preparing same | September 2022 | July 2025 | Allow | 34 | 0 | 1 | No | No |
| 17801237 | OPTICALLY RESOLVED TROLOX INTERMEDIATE AND METHOD FOR PRODUCING SAME | August 2022 | September 2025 | Allow | 37 | 0 | 0 | No | No |
| 17904592 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | August 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17800401 | BIOCONJUGATES AND ANTIBODIES FOR IMMUNODETECTION ASSISTED BY DERIVATIZATION OF THE MYCOTOXIN PATULIN | August 2022 | October 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17800309 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | August 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17631114 | WDR5-MYC INHIBITORS | August 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17796704 | SOLID STATE FORMS OF BLARCAMESINE SALTS | August 2022 | July 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17793172 | A CONTINUOUS FLOW PROCESS FOR PREPARATION OF ACEPHATE AND ITS INTERMEDIATES | July 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17785828 | PROCESS FOR THE PREPARATION OF PIPERIDINE COMPOUNDS | June 2022 | July 2025 | Allow | 37 | 1 | 0 | No | No |
| 17785713 | USE OF NAPHTHYLUREA COMPOUND | June 2022 | August 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17781777 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | June 2022 | January 2025 | Allow | 31 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VAJDA, KRISTIN ANN.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 35.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner VAJDA, KRISTIN ANN works in Art Unit 1622 and has examined 957 patent applications in our dataset. With an allowance rate of 88.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 16 months.
Examiner VAJDA, KRISTIN ANN's allowance rate of 88.4% places them in the 69% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by VAJDA, KRISTIN ANN receive 1.02 office actions before reaching final disposition. This places the examiner in the 10% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by VAJDA, KRISTIN ANN is 16 months. This places the examiner in the 98% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +11.1% benefit to allowance rate for applications examined by VAJDA, KRISTIN ANN. This interview benefit is in the 45% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 42.6% of applications are subsequently allowed. This success rate is in the 94% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 80.2% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 70.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.5% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.